Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA (pembrolizumab) for the Treatment of Small Cell Lung Cancer
Paul Quintaro